Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 160
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Low dividends
Data is available to registered users only
Data is available to registered users only
About
Sanjivani Paranteral Ltd. engages in the provision of pharmaceutical products. Its product category include antibiotic, anti-emetic, anti-diabetic, and anti-fungal. The company was founded by Anami H. Khemka, Ashwin A. Khemka, and Somesh Khemka on October 5, 1994 and is headquartered in Mumbai, India.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Data is available to registered users only
Buy
Sell